PCN115 COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN

✍ Scribed by SG Eggington; C Piñol; E Musi; A Valderrama

• Book ID: 118611958
• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 82 KB
• Volume: 12
• Category: Article
• ISSN: 1098-3015
• DOI: 10.1016/s1098-3015(10)74366-7